Calliditas Eyes Full Approval For Tarpeyo In IgAN After Positive Pivotal Update

Data from part B of the Swedish firm’s pivotal trial of Tarpeyo in the rare kidney disorder showed that the treatment effects lasted two years across the entire population, enabling the move from conditional to full approvals in several markets.